- Home
- SILO vs NXTC Comparison
SILO vs NXTC Comparison
Compare SILO & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- NXTC
- Stock Information
- Founded
- SILO 2010
- NXTC 2015
- Country
- SILO United States
- NXTC United States
- Employees
- SILO N/A
- NXTC N/A
- Industry
- SILO Apparel
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- SILO Consumer Discretionary
- NXTC Health Care
- Exchange
- SILO Nasdaq
- NXTC Nasdaq
- Market Cap
- SILO 8.8M
- NXTC 9.3M
- IPO Year
- SILO N/A
- NXTC 2019
- Fundamental
- Price
- SILO $0.84
- NXTC $0.42
- Analyst Decision
- SILO
- NXTC Strong Buy
- Analyst Count
- SILO 0
- NXTC 2
- Target Price
- SILO N/A
- NXTC $3.50
- AVG Volume (30 Days)
- SILO 175.9K
- NXTC 241.6K
- Earning Date
- SILO 05-16-2025
- NXTC 05-01-2025
- Dividend Yield
- SILO N/A
- NXTC N/A
- EPS Growth
- SILO N/A
- NXTC N/A
- EPS
- SILO N/A
- NXTC N/A
- Revenue
- SILO $72,102.00
- NXTC N/A
- Revenue This Year
- SILO $1.86
- NXTC N/A
- Revenue Next Year
- SILO N/A
- NXTC N/A
- P/E Ratio
- SILO N/A
- NXTC N/A
- Revenue Growth
- SILO N/A
- NXTC N/A
- 52 Week Low
- SILO $0.72
- NXTC $0.22
- 52 Week High
- SILO $4.50
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- SILO 35.28
- NXTC 47.10
- Support Level
- SILO $0.71
- NXTC $0.34
- Resistance Level
- SILO $0.85
- NXTC $0.52
- Average True Range (ATR)
- SILO 0.09
- NXTC 0.06
- MACD
- SILO -0.01
- NXTC 0.01
- Stochastic Oscillator
- SILO 21.85
- NXTC 45.14
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.